Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review proposes a theoretical model for treating androgenetic alopecia using STEAP3 protein, based on recent findings about genetic mutations affecting molecular pathways, but emphasizes that this hypothesis needs validation through laboratory and clinical studies.

This study found that cyproterone acetate treatment improved quality of life and reduced anxiety and depressive symptoms in women with skin manifestations of hyperandrogenism.

This study found that androgenetic alopecia in Chinese college students is more prevalent in males and is significantly associated with rosacea, with clinic patients experiencing a higher disease burden.

A 16-year-old girl's skin rash was likely caused by an infection and improved with topical steroids.

This article presents a case study of a 16-year-old male with GAPO syndrome, characterized by growth retardation, alopecia, pseudoanodontia, and optic atrophy, who sought dental treatment for missing teeth.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

This study found that a standardized PRP application protocol was effective as a coadjuvant therapy in most patients with androgenetic alopecia who did not respond to minoxidil or finasteride, based on improvements in Ebling's scale.

This study reports that Korean adolescents with androgenetic alopecia tend to have milder symptoms than adults and a higher prevalence of family history of alopecia.

This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair.

In this follow-up of three siblings with ATP6AP1 deficiency, the researchers observed progression to total hearing loss, hair loss, and proteinuria.

In a study on wound healing, researchers described injectable POEGMA‐DA hydrogels as a promising non-toxic alternative to traditional wound closure methods, showing effective tissue adhesion and enhanced regeneration of skin structures in a mouse model without significant inflammation.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

In this case report, a 36-year-old woman with GAPO syndrome underwent successful XEN gelatin micro-stent implantation in both eyes to control primary open-angle glaucoma that was unresponsive to medical treatment, marking the first documented use of this minimally invasive glaucoma surgery in such a patient.

RAGE is a potential target for melanoma treatment, but its effectiveness is uncertain due to variable expression levels.

This study found that increased mRNA expression of the Ectodysplasin-A2-Receptor, observed across multiple species and tissues, may exacerbate inflammation during aging, suggesting potential benefits of blocking EDA2R/EDA-A2 signaling.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

This study found that 1mg/d oral finasteride was effective and safe for treating androgenetic alopecia in men, with better results observed in patients aged 26 or younger.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

This report presents a case of acrodermatitis enteropathica in a 22-year-old female, highlighting the absence of underlying comorbid conditions.

This study found that among men with androgenetic alopecia, the M-type pattern, either isolated or combined with others, was observed most frequently, using the BASP classification.

This study found that after a 4-month comprehensive therapy course, 90.5% of patients with androgenetic alopecia and telogen effluvium showed hair condition improvement, highlighting the potential benefits of adjuvant proteoglycan replacement therapy in these conditions.

5% ET-02 is a more effective and safe treatment for hair loss than current options.

This study reported that microneedle-assisted delivery of PEGylated recombinant human fusion collagen significantly improved hair regrowth and density in an androgenetic alopecia mouse model and in a small clinical trial with AGA patients, suggesting potential efficacy and safety for this treatment approach.

This study developed an in vitro model using NTERT keratinocytes expressing AEC-related TP63 mutations, which replicated skin defects observed in AEC patients and offers a valuable tool for understanding the disorder and developing new treatments.

This study found no correlation between serum PSA levels and the severity of androgenetic alopecia at baseline in men.

This study reported significant improvements in hair density and growth ratio in androgenetic alopecia patients receiving concentrated growth factor injections, with benefits sustained for 6 months.

This letter discusses a case of erosive pustular dermatosis of the scalp linked to topical latanoprost use for androgenetic alopecia, but reports no clinical results.

This study found that a finasteride topical gel formulation using propylene glycol and Tween® 80 showed significantly enhanced permeation compared to a control formulation without these enhancers.

In this study, the ChatGPT-5 model accurately answered 76.47% of questions on the Polish endocrinology specialty exam, surpassing the 60% passing threshold, yet its role in clinical decision-making remains uncertain, highlighting the need for further research.